Physician profile
Jennifer M Fields
NPI 1104019835
$32,363.85
in general payments reported to CMS, 2019-2025
29 companies · $5,898 in 2025
The $5,898 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $5,310 · 2022: $8,173 · 2023: $7,737 · 2024: $5,246 · 2025: $5,898.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $12K · Food and Beverage: $6,687 · Travel and Lodging: $606.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $11,587.50 |
| Food and Beverage | $6,686.61 |
| Travel and Lodging | $606.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $24,949.48 | 2021-2025 | |
| Lilly USA, LLC | $3,411.52 | 2021-2023 | Emgality, Reyvow |
| Neurelis, INC. | $658.52 | 2021-2025 | Valtoco |
| Pfizer INC. | $627.93 | 2023-2025 | |
| Neurocrine Biosciences, INC. | $557.39 | 2022-2025 | Ingrezza, Ongentys |
| Tg Therapeutics, INC. | $288.39 | 2023-2025 | |
| Amgen INC. | $259.41 | 2021-2025 | Uplizna |
| E.R. Squibb & Sons, L.L.C. | $196.70 | 2022 | |
| Argenx US, INC. | $178.70 | 2022-2024 | Vyvgart Hytrulo, Vyvgart |
| Acadia Pharmaceuticals INC | $136.40 | 2025 | Daybue |
| Kyowa Kirin, INC. | $129.69 | 2022-2024 | Nourianz |
| Abbott Laboratories | $122.61 | 2021-2023 | Infinity |
| Vanda Pharmaceuticals INC. | $119.30 | 2024 | Ponvory |
| Sunovion Pharmaceuticals INC. | $106.57 | 2021 | |
| Medtronic, INC. | $105.44 | 2021-2025 | Percept PC Brainsense |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $90.94 | 2022-2023 | |
| Biogen, INC. | $62.66 | 2023-2025 | Tysabri, Vumerity |
| Supernus Pharmaceuticals, INC. | $52.94 | 2021-2025 | Qelbree |
| Lundbeck LLC | $50.98 | 2024-2025 | Vyepti |
| Amneal Pharmaceuticals LLC | $38.44 | 2024 | Rytary |
| Xeris Pharmaceuticals, INC. | $37.82 | 2024-2025 | Keveyis |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $36.09 | 2025 | Lifevest |
| Livanova USA, INC. | $28.06 | 2023 | Vns Therapy Sentiva Model 1000 Generator |
| Jazz Pharmaceuticals INC. | $26.18 | 2025 | |
| Mdd US Operations, LLC | $22.21 | 2025 | Gocovri |
| Emd Serono, INC. | $21.85 | 2025 | |
| Merz Pharmaceuticals, LLC | $17.66 | 2025 | Xeomin, Inbrija, Ampyra |
| Teva Pharmaceuticals USA, INC. | $17.31 | 2023 | Austedo |
| Biohaven Pharmaceutical Holding Company LTD. | $12.66 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Fields listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.